Seven Grand Managers LLC Purchases Shares of 30,000 Kymera Therapeutics, Inc. $KYMR

Seven Grand Managers LLC purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,000 shares of the company’s stock, valued at approximately $2,334,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after buying an additional 845,922 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Kymera Therapeutics by 11.0% during the fourth quarter. Geode Capital Management LLC now owns 1,417,389 shares of the company’s stock worth $110,307,000 after buying an additional 140,623 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after buying an additional 491,737 shares in the last quarter. Holocene Advisors LP purchased a new stake in Kymera Therapeutics during the third quarter worth $47,563,000. Finally, Commodore Capital LP purchased a new stake in Kymera Therapeutics during the second quarter worth $32,730,000.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $81.70 on Thursday. The company has a fifty day moving average of $83.28 and a two-hundred day moving average of $79.14. The stock has a market capitalization of $6.72 billion, a PE ratio of -22.89 and a beta of 2.06. Kymera Therapeutics, Inc. has a fifty-two week low of $28.33 and a fifty-two week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.82) earnings per share. Research analysts forecast that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Wall Street Analyst Weigh In

KYMR has been the topic of a number of recent analyst reports. UBS Group increased their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Morgan Stanley reissued an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a report on Thursday, April 30th. Citigroup increased their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Canaccord Genuity Group initiated coverage on shares of Kymera Therapeutics in a report on Wednesday, May 6th. They set a “buy” rating and a $106.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $118.10.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total value of $2,435,400.00. Following the transaction, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at approximately $54,081,710.10. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Bruce Booth sold 5,900 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the transaction, the director directly owned 5,641 shares in the company, valued at approximately $507,464.36. This represents a 51.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 370,918 shares of company stock valued at $31,120,324. Corporate insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.